F. Sanchez

Rituximab and CHOP chemotherapy plus GM-CSF for previously untreated diffuse large B-cell lymphoma in the elderly: a Wisconsin oncology network study.

KyungMann Kim, T. Saphner, S. Seo, 2010, Clinical lymphoma, myeloma & leukemia.

Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): Initial results from the MOUNTAINEER trial

N. Kemeny, A. Cercek, T. Bekaii-Saab, 2019, Annals of Oncology.

MOUNTAINEER:open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress).

E. Van Cutsem, J. Tabernero, A. Cercek, 2021 .

PULSE: A randomized phase II open label study of panitumumab rechallenge versus standard therapy after progression on anti-EGFR therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC).

H. Lenz, J. Larson, A. Cercek, 2021 .

Survival outcomes between surgery with adjuvant therapy compared to neoadjuvant therapy with surgery in stage I pancreatic adenocarcinoma: Results from a large national cancer database.

N. Guda, Maharaj Singh, J. Weese, 2019, Journal of Clinical Oncology.

Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial.

J. Fine, D. Kushner, J. Connor, 2007, Gynecologic oncology.

Preparing for Value-Based Cancer Care in a Multisite, Integrated Healthcare System

J. Weese, F. Sanchez, Marija Bjegovich-Weidman, 2017 .

Practice Model for Advanced Practice Providers in Oncology.

Laurie Williams, Katrin Goetzke, F. Sanchez, 2017, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Retrospective review of pegfilgrastim on-body injector delivery rates in a large health system.

F. Sanchez, M. Schober, P. Stuessy, 2017 .

Practice Model for Advanced Practice Providers in Oncology.

Laurie Williams, Katrin Goetzke, F. Sanchez, 2017, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

A phase II, open label study of tucatinib (ONT-380) combined with trastuzumab in patients with HER2+ metastatic colorectal cancer (mCRC)(MOUNTAINEER).

A. Grothey, A. Cercek, M. Fakih, 2017 .